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In this study, we investigated all Clostridioides difficile strains isolated from stool samples in Nagasaki
University Hospital between January 2012 and December 2014. Toxin genes (tcdA, tcdB and cdtA/cdtB)
were analyzed for multiplex PCR in a total of 213 strains. In the toxin gene-positive strain, PCR ribotyping
was conducted using capillary gel electrophoresis-based PCR and the Webribo database. Patients’
backgrounds were analyzed by departments, disorders, antimicrobials, and clinical dates. The positive
rates of tcdA, tcdB, and cdtA/cdtB genes were 62.9%, 63.4%, and 2.8%, respectively. The most frequent PCR
ribotype was 047 (14.1%), followed by 014/0 (11.1%) and 002/0 (8.2%). In univariate analysis, the risk
factors for the detection of toxin gene-positive strains in patients were older age (p ¼ 0.0036), over  65
years old (p ¼ 0.0175), the patients hospitalized at Department of Digestive Surgery (P ¼ 0.0059), higher
CRP level (P ¼ 0.0395), and lower albumin level (p ¼ 0.0014). In the multivariate analysis, the risk factor
for detection of toxin gene-positive strains was the patients hospitalized at Department of Digestive
Surgery (OR; 4.62, 95% CI; 1.18e18.0, p ¼ 0.0274). In this study, the percentage of toxin gene-positive and
cdtA/cdtB gene-positive strains was almost the same as that reported in previous studies, but the ribotype
was different. In addition, we revealed that the risk factor associated with the detection of toxin gene-
positive strains was the patients hospitalized at Department of digestive surgery.
© 2018 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
Clostridioides difficile is a gram-positive anaerobic bacterium and
a causative pathogen of antibiotic-associated diarrhea (AAC) [1]. In
C. difficile infections (CDIs), toxin A and B play important roles [2,3].
Both toxins have cytotoxic activities and induce the release of
various immunomodulatory mediators from epithelial cells,
phagocytes, and mast cells [2]. Recently, the spread of binary toxin
(CDT)-producing strains has raised a major concern in the United
States and Europe. CDT-producing strains are highly resistant to
fluoroquinolones and increase mortality [4e6]. In European Society
of Clinical Microbiology and Infectious Diseases (ESCMID) guideline
for the diagnosis of CDI, glutamate dehydrogenase (GDH) screening
test, toxin A and toxin B EIA testing, and nucleic acid amplification
tests (NAATs) for toxin genes are recommended [7].edicine, Nagasaki University
to, Nagasaki 852-8501, Japan.
d The Japanese Association for InfectiAlthough the sensitivities of NAATs were higher than that of the
EIA test, it was difficult to conduct NAATs on all specimens in
routine examinations, because of the high cost and labor involved.
The first European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) guideline recommend a two-step algorithm:
first, samples should be analyzed by EIA testing; if the result is
positive for GDH and negative for toxin A/B, samples are then
analyzed by NAATs [7]. Recently, the fully automated molecular test
(FAMT) has been developed, making it easier to perform NAATs
[8,9] and allowing for the detection of CDT. Many hospitals are
expected to implement the NAATs including FAMT, but there have
been fewmolecular epidemiological studies of C. difficile and CDT in
Japan [10e12].
In this study, we investigated the molecular epidemiology of
C. difficile. Additionally, to clarify the patients who were recom-
mended for performance of the NAATs, we investigated and
compared the patients' backgrounds between toxin-positive and
-negative C. difficile to clarify the risk factors for CDI.ous Diseases. Published by Elsevier Ltd. All rights reserved.
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2.1. Study design and sample collection
This study was conducted between January 2012 and December
2014. This study was approved by the ethics committee of Nagasaki
University Hospital (13062425). We collected C. difficile isolated
from stool samples between January 2012 and December 2014 in
Nagasaki University Hospital. To avoid duplicates, only the first
isolate from each patient was collected.
The patient background information, such as age, gender, length
of hospitalization, underlying diseases, history of surgery within 90
days before submission of stool sample, length of hospitalization
before submission of stool sample, oral and intravenous adminis-
tration of antimicrobial agents, use of proton pump inhibitors
(PPIs), and use of histamine-2 receptor antagonists (H2 blockers)
within 60 days before submission of stool sample, CDI symptoms
associated with CDI, and mortality rate were analyzed. We defined
administration of metronidazole and oral vancomycin after sub-
mission of stool sample as CDI treatment. Because we did not
evaluate the Bristol scale in the laboratory during the study period,
we investigated the development of diarrhea, based on medical
record.We also investigated the laboratory data for white blood cell
count ( 103/ml), red blood cell count ( 106/ml), C-reactive protein
(CRP) (mg/dl), blood urea nitrogen (BUN) (mg/dl), serum creatinine
(mg/dl), uric acid (UA) (mg/dl), total protein (TP) (g/dl), albumin (g/
dl), and lactate dehydrogenase (LD) (U/l) at one day before and after
submission of the stool sample.
2.2. Genetic analysis
In this study, we used the ATCC9689 strain as a positive control.
We inoculated all C. difficile strains with cycloserine-cefoxitin
mannitol agar (CCMA; Nissui Pharmaceutical Co., Ltd., Japan). The
plates were incubated at 37 C for 48e72 h under anaerobic con-
ditions. Bacterial DNA was extracted by using Achromopeptidase
solution (Wako Chemical Co., Ltd., Osaka, Japan), 10% Chelex-100
(Bio-Rad Laboratories, Hercules, CA, USA), and the boiling method
[13]. We confirmed the genes for toxins (tcdA and tcdB), CDT (cdtA
and cdtB), and 16S rRNA by PCR as previously described [14]. The
16S rRNA primers were as follows: forward 8UA, 50-AGAGTTT-
GATCMTGGCTCAG-3’; and reverse 1458B, 50-TACGGTTACCTTGT-
TACGAC-3’ [15].
PCR ribotyping was evaluated by capillary gel electrophoresis-
based PCR, which was performed according to the protocol of a
previous study [16]. In this method, we used the AppliedFig. 1. Analysis of C. difficile isolates. C. difficile isolated from stool sample of 213 patients wer
for PCR ribotype (n ¼ 135).Biosystems 3130 genetic analyzer with POP7 polymer (Applied
Biosystems, Foster City, CA, USA) and GeneScan-1200Liz size
standard (Applied Biosystems). The size of each peak was deter-
mined using Peak Scanner software v1.0 (Life Technologies, Carls-
bad, CA), and PCR ribotypes were determined by the Webribo
database of the Austrian Agency for Health and Food Safety
(https://webribo.ages.at).
We defined a following situation as outbreak, based on the
notification from Regional Medical Care Planning Devision, Healthy
Policy Bureau, Ministry of Health, Labor and Welfare, Japan
(December 19, 2014): same PCR ribotype strain was isolated from
three or more patients hospitalized in same ward within 4 weeks.
2.3. Statistical analysis
The statistical software used in this study was JMP Pro 10.0.2
(SAS Institute Inc, Cary NC, USA). Continuous variables were
compared using the Student's t-test. The chi-square was used to
compare categorical variables. Variables with a P value less than
0.20 according to the univariate analysis were considered for in-




C. difficile strains were isolated from a total of 213 (122 men and
91 women) patients during the study period (Fig. 1). The positive
rates of tcdA, tcdB, and CDT genes were 62.9% (n ¼ 134), 63.4%
(n ¼ 135), and 2.8% (n ¼ 6), respectively. We defined strains
harboring the tcdA and/or tcdB genes as toxin gene-positive strains.
Among the toxin gene-positive strains, the positive rate of CDTgene
was 4.4%.
PCR ribotyping was performed on toxin gene-positive strains
(Table 1). The most frequent PCR ribotype was the 047 strain
(14.1%), followed by 014/0 (11.1%), 002/0 (8.2%), 020 (6.7%), and 018
(4.4%). The PCR ribotypes of CDT-positive strains were 016 (two
strains), 131 (three strains), and 413 (one strain). There was no
outbreak of each PCR ribotype in this study.
3.2. Comparison of toxin gens-positive and -negative strains
The patient backgrounds with toxin gene-positive and -negative
strains are shown in Table 2. The average age of the patients was
significantly higher in patients with toxin gene-positive strainse analyzed for toxin genes by multiplex PCR. Toxin genes-positive strains were analyzed
Table 1

























Other: less than 1%.
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(p ¼ 0.0034). There were significant differences between the two
groups in terms of the inpatient department. The percentage of
patients with toxin gene-positive strains who were hospitalized at
the Department of Pediatrics was significantly lower in patientsTable 2
Comparison of the patient background between the patients toxin genes-positive and n
Background Total (n ¼ 213) Patients with
genes-positiv
Age 49.9 ± 28.4 54.2 ± 26.5
<15 years old 49 (23.0%) 23 (17.0%)
65 years old 91 (42.7%) 66 (48.9%)
Sex (male %) 122 (57.3%) 80 (59.3%)
Length of hospitalization (day) 32.3 ± 55.8 33.2 ± 60.2
Diarrhea (%) 128 (60.1%) 83 (61.5%)
Abdominal tenderness 59 (27.7%) 39 (28.9%)
Temperature (38.5 C) 49 (23.0%) 29 (21.5%)
Previous surgery within 90 days 36 (16.9%) 25 (18.6%)
Mortality within 90 days 24 (11.3%) 15 (11.1%)
Treatment with CDI (vancomycin
or metronidazole)
44 (20.7%) 33 (24.4%)
Department
Hematology 47 (22.1%) 30 (22.2%)
Pediatrics 46 (21.6%) 21 (15.6%)
Gastroenterology 44 (20.7%) 28 (20.7%)
Digestive Surgery 31 (14.6%) 27 (20.0%)
Respiratory medicine 11 (5.2%) 9 (6.7%)
Anesthesiology 7 (3.3%) 4 (3.0%)
Disorder
Hematology 54 (25.4%) 33 (24.4%)
Liver 41 (19.2%) 26 (19.2%)
Kidney 12 (5.6%) 7 (5.2%)
Intestinal diseases 27 (12.7%) 21 (15.7%)
Cardiac 12 (5.6%) 9 (6.7%)
Laboratory data
White Blood Cell (  103/ml) 7.5 ± 6.6 7.4 ± 6.2
Red Blood Cell (  106/ml) 3.4 ± 0.8 3.4 ± 0.7
C-reactive protein (mg/dl) 5.1 ± 6.1 5.8 ± 6.5
Blood urea nitrogen (mg/dl) 19.1 ± 15.0 19.8 ± 16.4
Serum creatinine (mg/dl) 0.9 ± 1.1 1.0 ± 1.0
Uric acid (mg/dl) 4.5 ± 2.3 4.8 ± 2.6
Total protein (g/dl) 6.2 ± 1.0 6.2 ± 1.0
Albumin (g/dl) 3.1 ± 0.7 3.0 ± 0.7
Lactate dehydrogenase (U/l) 246.9 ± 160.6 244.0 ± 179.with toxin-positive gene (25 patients, 15.6%) than in those with
toxin gene-negative strains (25 patients, 32.1%) (p ¼ 0.0055). In
contrast, the percentage of patients with toxin gene-positive strains
who were hospitalized at the Department of Digestive Surgery was
significantly higher than in patients with toxin-positive gene
strains (27 patients, 20.0%) than in those with toxin gene-negative
strains (four patients, 5.2%) (p ¼ 0.0015). When analyzing the lab-
oratory data, the serum albumin levels in patients with toxin gene-
positive strains was significantly lower (3.0 ± 0.7 g/dl) than in those
with toxin gene-negative strains (3.3 ± 0.7 g/dl) (p ¼ 0.0017).
Administration of antimicrobials, PPIs, and H2 blockers and
antimicrobial agents is summarized in Table 3. The PPIs, H2
blockers, and antimicrobial agents were administered to 84 pa-
tients (39.4%), 15 patients (7.0%), and 157 patients (70.5%), respec-
tively. The percentage of those administered with macrolides was
significantly higher in the patients with toxin gene-positive strains
(seven patients, 5.2%) than in those with gene-negative strains (0
patients, 0.0%) (p ¼ 0.0107).3.3. Risk factor for detection of toxin gene-positive strains
We compared the background of the patients with toxin gene-
positive and -negative strains by univariate and multivariate ana-
lyses to clarify the risk factors for the detection of toxin gene-
positive strains (Table 4). In the univariate analysis, the risk fac-
tors for the detection of toxin genes positive-strain were older age
(OR, 0.99; 95% CI, 0.98e1.00; p ¼ 0.0036), over  65 years old (OR,
2.03; 95% CI, 1.13e3.63; p ¼ 0.0175), patients hospitalized at the
Department of Digestive Surgery (OR, 4.63; 95% CI, 1.55e13.8;
p ¼ 0.0059), higher CRP level (OR, 0.94; 95% CI, 0.89e1.00;egative strains.
toxin
e strain (n ¼ 135)
Patients with toxin
genes-negative strain (n ¼ 78)
P value






















7.7 ± 7.4 0.9546
3.5 ± 0.8 0.3977
3.9 ± 5.1 0.0565
17.8 ± 11.9 0.5033
0.9 ± 1.3 0.0659
4.2 ± 1.7 0.6126
6.4 ± 0.9 0.2012
3.3 ± 0.7 0.0017
9 252.5 ± 116.2 0.1717
Table 3
Comparison of administration of PPI, H2 blocker and antimicrobial agents between the patients with toxin genes-positive and negative strains.
Variable Total (n ¼ 213) Patients with toxin
genes-positive strain (n ¼ 135)
Patients with toxin
genes-negative strain (n ¼ 78)
P value
PPIs 84 (39.4%) 54 (40.0%) 30 (38.5%) 0.8247
H2 blocker 15 (7.0%) 9 (6.7%) 6 (7.7%) 0.7793
Administration of antimicrobial
agents within 60 days
157 (73.7%) 102 (75.6%) 55 (70.5%) 0.4288
Penicillin 49 (23.0%) 31 (23.0%) 18 (23.1%) 0.9848
Cephalosporin 81 (38.0%) 51 (37.8%) 30 (38.5%) 0.9211
1st generation Cephalosporin 17 (8.0%) 12 (8.9%) 5 (6.4%) 0.5139
2nd generation Cephalosporin 7 (3.3%) 3 (2.2%) 4 (5.1%) 0.2625
3rd generation Cephalosporin 15 (7.0%) 12 (8.9%) 3 (3.8%) 0.1478
4th generation Cephalosporin 48 (22.5%) 28 (20.7%) 20 (25.6%) 0.4124
Carbapenems 64 (30.0%) 40 (29.6%) 24 (30.8%) 0.8614
Aminoglycoside 7 (3.3%) 4 (3.0%) 3 (3.8%) 0.7302
Fluoroquinolones 30 (14.1%) 20 (14.8%) 10 (12.8%) 0.6852
Macrolides 7 (3.3%) 7 (5.2%) 0 (0.0%) 0.0107
PPI, proton pump inhibitors.
Table 4
Univariate and multivariate analysis of the risk factor for the detection of toxin genes-positive strains.
Risk factor Univariate analysis Multivariate analysis
Odds ratio 95% CI P value Odds ratio 95% CI P value
Age 0.99 0.98e1.00 0.0036 1.01 0.96e1.06 0.7574
<15 years old 0.41 0.21e0.79 0.0073 e e e
65 years old 2.03 1.13e3.63 0.0175 1.67 0.44e6.37 0.4495
Department of Pediatrics 0.39 0.20e0.76 0.0056 e e e
Department of Digestive Surgery 4.63 1.55e13.8 0.0059 4.62 1.18e18.0 0.0274
Intestinal diseases 2.21 0.85e5.74 0.1032 1.28 0.38e4.28 0.6915
C-reaction protein (mg/dl) 0.94 0.89e1.00 0.0395 0.97 0.91e1.04 0.3974
Albumin (g/dl) 2.02 1.29e3.14 0.0014 1.51 0.80e2.84 0.2010
Administration of 3rd generation Cephalosporin within 60 days 2.44 0.67e8.93 0.1478 7.22 0.85e61.0 0.0694
Multivariate analysis; Predictors with a P value < 0.20 in the univariate analysis were included in forward stepwise multivariate logistic regression analysis.
Y. Okada et al. / J Infect Chemother 25 (2019) 262e266 265p ¼ 0.0395), and lower albumin level (OR, 2.02; 95% CI, 1.29e3.14;
P ¼ 0.0014). In the multivariate analysis, the risk factors for the
detection of toxin gene-positive strains were patients hospitalized
at Department of Digestive Surgery (OR, 4.62; 95% CI, 1.18e18.0;
p ¼ 0.0274).
3.4. Characteristics of the patients with CDT gene-positive strains
CDT gene-positive strains were cultured from 6 patients (3 men
and 3 women). The age range was 5e84 years, and the patients
under 18 years included 2 patients. All patients had diarrhea, 3 had
temperatures of over 38.5 C, and the white blood cell count was
high only in one case (29,700/ml). There were no severe cases, such
as pseudomembranous enteritis, in the 6 patients. Treatment with
CDI (vancomycin or metronidazole) was administered only in 3
cases. All cases were cured from CDI.
4. Discussion
This study revealed the molecular epidemiology of C. difficile
and risk factors for the detection of toxin gene-positive strains. In a
previous Japanese study, the percentage of toxin gene-positive
strains and CDT gene-positive strains was 73% and 2%, respec-
tively [10]. In other Japanese study, CDT-gene positive strains was
5% [17]. In comparison with the previous studies, the percentage of
toxin gene-positive strains that was lower than that of CDT gene-
positive strains was nearly the same in this study. The lower per-
centage of toxin gene-positive strain was caused by a difference in
collection of samples. The previous report investigated suspected
CDI, but in this study, we investigated all strains cultured from stool
samples. Therefore, our study involved the patients withcolonization of C. difficile. The percentage of CDT gene-positive
strain in Japan seemed to be lower than that in other countries:
the percentage of CDT gene-positive strain in Colombia was 17.5%
[18]; in United Kingdom and Finland, the percentage of CDT gene-
positive strains was 16.9% and 37%, respectively [19,20]. Addition-
ally, in this study, we did not detect NAP1/027 and 078 strains,
which were reported as the causative pathogens of serious and
epidemic CDI in Europe and United States [21]. The PCR ribotype of
CDT gene-positive strains in this study was 016, 131, and 413.
In this study, we clarified the PCR ribotype in all toxin gene-
positive strains. The most frequent ribotypes as revealed by PCR
for toxin gene-positive strains were 047, 014/0, and 020 in this
study. In a previous Japanese study, the ribotypes present at a high
frequency were strains 018, 002, 052, and 369 [22]. In other Japa-
nese study, the ribotypes present at a high frequency was strains
449 [17]. The frequent PCR ribotypes varied by the studies in Japan
[17,22]. In the United States, the most frequent PCR ribotypes were
strains 002, 014e020, 027, and 053e163 [23], but themost frequent
PCR ribotypes were different according to area. Other reports from
the United States revealed that the most frequent PCR ribotypes in
the northeast, southern, midwestern, and western United States
were 027, 014/020, 106, 001, 053, respectively [24]. We hypothe-
sized that ribotypes differed from area to area, and that it is
important to conduct surveillance in each area. Additionally, 42% of
the PCR ribotype strain 047 was detected from the patients at
Department of Digestive Surgery in this study, but we did not
observe outbreak of the strain. This result was indicating that
epidemic ribotypes differed from ward to ward.
We investigated the risk factors for the detection of toxin-
positive strains by comparing the characteristics of patients with
toxin gene-positive and negative strains. In the univariate analysis,
Y. Okada et al. / J Infect Chemother 25 (2019) 262e266266there was no significant difference in the administration history of
the antimicrobial drugs or the type of antibiotics between the pa-
tients with toxin gene-positive and -negative strains. Since the
antimicrobial drug administration history was observed at almost
the same ratio in both groups, administration of antimicrobial
drugs may lead to the colonization of C. difficile. In the analysis of
laboratory data, the patients with toxin gene-positive strains
showed higher CRP and lower albumin levels. However, there were
no significant differences in themultivariate analysis. It seems to be
difficult to discriminate between the presence or absence of toxin
gene-positive strains by using laboratory data. In the multivariate
analysis, the risk factors for the detection of toxin gene-positive
strains included hospitalized patients at the Department of Diges-
tive Surgery. On the other hand, if C. difficile was detected in chil-
dren, the possibility that theywere also positive for toxin genes was
relatively low in this study. A previous report revealed that CDI was
more frequently caused in solid-organ transplant recipients than in
other hospitalized patients, because solid-organ transplant re-
cipients had a several CDI risk factors, such as PPIs, H2 blockers, age
greater than 65 years old, severe underlying disease, uremia,
gastrointestinal surgery, presence of nasogastric or endotracheal
tube, and prolonged hospitalization [25]. The Department of
Digestive Surgery in our hospital conducts solid-organ transplants,
and it seemed to have had an influence on the higher percentage of
toxin gene-positive strains in the Department of Digestive Surgery.
There were some limitations in this study. First, we studied only
C. difficile strains cultured from stool samples, and CDIs diagnosed
by only enzyme immunoassays were not included in this study.
Second, we could not investigate the Bristol scale. If we could
investigate the Bristol scale, we would evaluate the association
between diarrhea condition and harboring toxin genes including
Bristol scale. Third, we did not determine the PCR ribotype of toxin
gene-negative strains. The PCR ribotype of the toxin gene-negative
strains remained unknown. It is necessary to understand the ten-
dency to colonized C. difficilewith toxin negative strains. Therefore,
further investigations are needed.
5. Conclusion
In this study, the percentages of toxin gene-positive and CDT
gene-positive strains were almost the same as those reported in
previous studies, but the ribotypes differed. In addition, we
revealed that the risk factors associated with the detection of toxin
gene-positive strains included patients hospitalized at the
Department of Digestive Surgery.
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